Corvus Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Corvus Pharmaceuticals, Inc. (CRVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $9.09 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2022-03-10
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $9.09, a 11.14% decline from fiscal 2020.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2020 was $10.23, a 12.26% decline from fiscal 2019.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2019 was $11.66, a 0.52% increase from fiscal 2018.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2018 was $11.60, a 1.75% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2021-12-31 | $9.09 10-K · filed 2022-03-10 |
| 2020-12-31 | $10.23 10-K · filed 2022-03-10 |
| 2019-12-31 | $11.66 10-K · filed 2021-03-25 |
| 2018-12-31 | $11.60 10-K · filed 2020-03-09 |
| 2017-12-31 | $11.40 10-K · filed 2019-03-07 |
| 2016-12-31 | $8.02 10-K · filed 2018-03-01 |
| 2015-12-31 | $0.28 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |